Abstract

FORMULATION OF CARBAMAZEPINE CONTROLLED RELEASE BUCCAL TABLET AS A TREATMENT OF EPILEPSY

Belsarkar A. S.*, Sul K. T. and More A. V.

ABSTRACT

Carbamazepine, a Dibenzazepine derivative, is used to treat a variety of disorders, including epilepsy, trigeminal neuralgia, and bipolar disorder. Carbamazepine is the most effective and affordable first-line medication for seizures (CBZ). The Biopharmaceutical Classification System classifies them as BCS class II compounds because of their strong membrane permeability and poor water solubility, which make dissolution the rate-limiting stage in the absorption process. The brain is a delicate and highly complicated organ. All of our actions, motions, perceptions, thoughts, and emotions are controlled and regulated by it. To get around issues like high hepatic first pass metabolism and related adverse medication reactions, buccal drug delivery is an alternative to the traditional form of drug administration. Polyethylene glycols 6000 (PEG) are substances that improve a compound's ability to dissolve in water or other aqueous mediums. This will aid in the drug's optimal rate and extent of release. As a result, the solubility restriction in salivary secretion can be overcome, which eventually aids in improving the buccal bioavailability of Carbamazepine. As a result, it was determined to create a formulation of a controlled-release buccal tablet of carbamazepine, optimise it using experimental formulation design, and assess its various evaluation parameters, including drug release profile, mucoadhesion force, mucoadhesion time, etc.

Keywords: Carbamazepine, Buccal, Tablets, Formulation, Epilepsy, Mucoadhesion.